Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicenter, single-arm, open-label, phase II study evaluating the efficacy and safety of lenalidomide, anti-PD-1 antibody combined with orelabrutinib or rituximab in R/R DLBCL

Next Previous
Trial Profile

A prospective, multicenter, single-arm, open-label, phase II study evaluating the efficacy and safety of lenalidomide, anti-PD-1 antibody combined with orelabrutinib or rituximab in R/R DLBCL

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Orelabrutinib (Primary) ; Rituximab (Primary) ; Tislelizumab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 18 Jan 2023 New trial record
  • 13 Dec 2022 Results (n=9), presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top